Promega builds plant to produce regulated products

Published: 29-Aug-2011
Manufacturing Analysis

Including sample preparation systems and reagents

Promega Corporation, based in Madison, Wisconsin, US, has held a ground-breaking ceremony for a new cGMP facility to support business growth and customers who need FDA-regulated molecular biology products. These include sample preparation systems and reagents, which are part of diagnostic and medical tests sold by human diagnostic test providers.

The 260,000ft2 (24,150m2) facility will require an additional 100 people in the next five years. Most of the building will be dedicated to fixed and flexible manufacturing areas. It will also house a customer experience centre for training, laboratory demonstrations and conferences.

‘This building is our next step in expanding our product supply capabilities worldwide,’ said ceo Bill Linton.

Plans include a number of sustainable practices, including geothermal heating and cooling, dark sky compliant lighting, prairie restoration, bio-retention ponds for storm water run off among other sustainable features and construction practices.

Promega Corporation provides solutions and technical support to the life sciences industry. Its 2,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification.

See more

You may also like

Manufacturing

Promega opens new Shanghai facility

Read more
Provides additional r&d and cGMP manufacturing capabilities

Trending Articles

  1. ACG at Pharma Pro&Pack 2025 ACG to showcase world-class machinery, inspection systems, and process optimisation at Pharma Pro&Pack 2025
  2. Hovione and Microinnova team up to advance modular flow chemistry for multi-purpose manufacturing The modular approach will enable faster process transfer, sustainable operations and fully integrated development solutions
  3. Developing strategies for robust chemistry, manufacturing and controls execution for advanced biologics Chemistry, manufacturing and controls (CMC) is a fundamental discipline for complex drug development projects. It must be rigorously implemented to navigate stringent regulatory requirements before drug approval and commercialisation
  4. Gerresheimer and Portal Instruments team up to commercialise PRIME Nexus reusable autoinjector Gerresheimer and Portal Instruments are joining forces to develop and manufacture the PRIME Nexus syringe-based, reusable, connected autoinjector platform, offering pharmaceutical companies an end-to-end solution for delivering chronic disease therapies
  5. Guardtech Cleanroom Ltd Industry-leading providers of bespoke laboratory design & build solutions, as well as a wide array of high-quality cleanroom-related products and services – including comprehensive decontamination and maintenance programmes

Upcoming event

CPHI Frankfurt 2025

28–30 October 2025 | Exhibition | Frankfurt, Germany See all

You may also like

Manufacturing

Promega opens new Shanghai facility

Provides additional r&d and cGMP manufacturing capabilities
Manufacturing

Automate Reactex glass reactor systems easily with Hitec Zang

Labtex, backed by more than 20 years of expertise in specialist laboratory and process chemistry equipment, is bringing advanced automation to its REACTEX glass reactor systems through innovative solutions from Hitec Zang
Manufacturing

Rezon Bio launches as European biologics CDMO with mirrored sites in Poland

New CDMO combines cost efficiency, digital innovation and EMA/FDA-audited facilities in Gdańsk and Warsaw to accelerate biologics development and commercialisation
Manufacturing

RION engages Lonza to scale manufacturing exosome based therapeutics

Collaboration leverages RION’s proprietary biomanufacturing process to propel RION’s industry-leading clinical development pipeline towards late-phase trials and commercialisation for multiple regenerative medical conditions
Manufacturing

Quantoom Biosciences partners with Memorial Sloan Kettering Cancer Center to advance personalised mRNA cancer therapeutics

Quantoom Biosciences will use MSK's proprietary lipid nanoparticle technology, Ncapsulate QCX-002, in the development of personalised RNA-based cancer therapies, with plans to support upcoming Phase I clinical trials
You need to be a subscriber to read this article.
Click here to find out more.
Analysis

The long and short of it: a new way to analyse ultrashort-, short- and long-chain PFAS simultaneously (part I)

SCIEX PFAS expert, Craig Butt (pictured), explores innovative methods that enable the rapid, sensitive detection and monitoring of ultrashort-, short- and long-chain PFAS in complex environmental matrices such as air and seawater
Manufacturing

Baxter earns first Gold Resiliency Badge from HIRC across IV, nutrition and premix drug categories

The company is the first manufacturer to receive the Healthcare Industry Resilience Collaborative’s gold badge for IV solutions, nutrition solutions and premix drugs, recognising its leadership in building a transparent, reliable and disruption-ready healthcare supply chain
Subscribe now